Form D · Pharmaceuticals
Telomir Pharmaceuticals, Inc.
Tampa, FL · CIK 0001971532
Offering snapshot reported Apr 3, 2023 · SEC filing
- Reported sold
- $1M Offering amount: $1M
- Investors reported
- 10 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 15, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 3, 2023 | Initial | $1,000,000 | No comparison | 10 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $90K
- Finders' fees
- $0
- Form D file number
- 021-477688
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Skyway Capital Markets, LLC | 124630 |
Source: Form D, filed Apr 3, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Chris Chapman | Director, Executive |
| Craig Eagle | Director |
| Hugh Mc Coll | Director |
| James Mc Nulty | Executive |
| Tuck Talhia | Director |
| Jude Uzonwanne | Director |
| David Vorhoff | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
900 West Platt Street, Suite 200
Tampa, FL, 33606
Tampa, FL, 33606